^
Association details:
| Biomarker: | SBS5 signature |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
Published date:
09/25/2020
Excerpt:
In this study, BRCA2 mutated tumors were, similar to ERCC2 mutated tumors, associated with high numbers of mutations in a SBS5 context, indicating that this mutational signature is an indicator of a DDR-deficient tumor that may be more sensitive to chemotherapy. This is also in line with our findings that ERCC2 mutations per se were not associated with treatment response in this cohort - but the SBS5 mutational signature was.
DOI:
doi.org/10.1038/s41467-020-18640-0